Welcome to the Reuters.com BETA. Read our Editor's note on how we're helping professionals make smart decisions.
Skip to main content


Russia's RDIF expects EMA approval of Sputnik V COVID-19 vaccine within two months -Ifax

1 minute read

Doses of the Sputnik V vaccine against the coronavirus disease (COVID-19) are seen at a vaccination centre in Zilina, Slovakia June 7, 2021. REUTERS/Radovan Stoklasa/File Photo

MOSCOW, June 16 (Reuters) - Russia's RDIF sovereign wealth fund expects to receive approval for the Sputnik V vaccine against COVID-19 from the European Medicines Agency within two months, the Interfax news agency reported on Wednesday.

Reuters reported earlier on Wednesday that European Union approval of Sputnik V will be delayed because a June 10 deadline to submit data was missed, citing two people familiar with the matter. read more

Reporting by Maria Kiselyova; Writing by Alexander Marrow; editing by Louise Heavens

Our Standards: The Thomson Reuters Trust Principles.

More from Reuters